Abstract: The outcome of ocular manifestations of Behcet’s Disease remains uncertain and unpredictable despite cytotxic drugs. One of our recent studies, presented to the 1995 Korean Rheumatology Annual Meeting, showed that one third of patients were None Responders, regardless of what treatment used. This study was designed to search for factors predicting the final outcome at the beginning of the treatment. Patients having more than one year of treatment were selected ...
Abstract: The pathergy phenomenon (PP) is one of the hallmarks of Behcet's Disease (BD). It has been reported to be positive from 17.5% to 83% of cases in different studies. PP is used as a diagnosis criterion in the Dilsen criteria, the Japan criteria, the International criteria, and the Iran criteria. It is therefore important to know wether PP is a fix manifestation of the disease or a cyclic manifestation ...
Abstract: INTRODUCTION: The pathergy phenomenon (PP) is one of the hallmarks of Behcet's Disease (BD). It has been reported to be positive from 17.5% to 83% of cases in different studies. PP is used as a diagnosis criterion in the Dilsen criteria, the Japan criteria, the International criteria, and the Iran criteria. It is therefore important to know whether PP is a fix manifestation of the disease or a cyclic manifestation ...
Abstract: Behcet’s Unite, Shariati Hospital the aim to propose a scoring system for the treatment of the ocular inflammation one vasculitis by our medications and to evaluate the state of the activity of the eye. Eleven activity and five chronicity (constant) parameters are scored from zero to four to consider the condition of each eye. The activity variables are: episcleritis &/or scleritis, anterior uveitis, hyalites, IMU, central periphlebitis &/or thrombosis, central periartertis, peripheral ...
Abstract: Introduction: Opthalmologic manifestations are the major cause of morbidity in Behcet’s Disease. If not treated, they usually progress toward sever loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents. Materials & Methods: In an open, non randomized, control study, pulse cyclophosphamide (PCP), low dose pulse cyclophosphamide (LDP), weakly methtrexate (MTX), chlorambucil (CHL), oral cyclophosphamide (OCP), and cyclosporine A (CYA) were used in a standard protocol for 778 patients. ...
Abstract: There are only two nationwide surveys of Behcet's Disease (BD) in the world, one from Japan and one from Iran. The comparison of the two surveys is interesting because the populations are racially different, although they share same genetic background via the invasion of Iran by Turk tribes (from the northem part of China) in the 10 th and 13 th century. The annual incidence of BD in Iran is 350 ...
Abstract: Porpose: To determine the risk factors in the prognosis and the visual outcome of the disease. Methods: This is a retrospective study of 361 patients, having Behcet’s disease and treated by immunosuppressives and steroids, followed-up at Shariatti Hospital (mean duration of follow-up was 2.27 years). The ocular examinations at the first and last visit are recorded and compared. Results: Vision ...
Abstract: Results of PCP are well known in lupus nephritis. We present here it’s outcome in patients with WHO type IV lupus nephritis, treated before the occurrence of renal failure. Patients having a follow up of more than 36 months were selected for this study. 29 patients fulfilled the selection criteria. Proteinuria, hematuria, leucocyturia, cast, BUN, creatinine and blood pressure were measured before PCP and after each one. The first and ...
Abstract: In a study on 391 cases of BD presented to the EULAR Congress in 1987 we demonstrated that the following symptoms were seen more frequently in patients with positive pathergy phenomenon: oral aphthosis as the initial manifestation of the disease, genital ulcerations, pseudofolliculitis, and arthralgia. The following symptoms, on the contrary were seen less frequently: oral aphthosis, ankylosing spondylitis. It was interesting to look after those findings, 6 years later, in ...
Abstract: Pulse cyclophosphamide (PCP) is the most effective and the least toxic treatment in posterior uveitis (pU) and/or retinal vasculitis (RV) of Behcet's disease (BD). Conventional doses (1 g/m2) may be associated with minor side effects such as hair loss, nausea and vomiting. To find whether lower doses, such as those already employed in Lupus nephritis should be useful, we administered IVLDP (0.5 g/m2/month) plus prednisolone (0.5 mg/kg/day) to 40 BD ...